Ocular Therapeutix Inc (OCUL)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Antony Mattessich
Employees:
230
15 CROSBY DRIVE, BEDFORD, MA 01730
781-895-3235

Ocular Therapeutix, Inc. focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases.

Data derived from most recent annual or quarterly report
Market Cap 395.063 Million Shares Outstanding77.01 Million Avg 30-day Volume 1.124 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.31
Price to Revenue13.1582 Debt to Equity0.5845 EBITDA7.134 Million
Price to Book Value6.5077 Operating Margin-179.3047 Enterprise Value459.941 Million
Current Ratio7.264 EPS Growth0.617 Quick Ratio7.036
1 Yr BETA 1.6034 52-week High/Low 6.53 / 2.57 Profit Margin-15.0568
Operating Cash Flow Growth-22.3998 Altman Z-Score0.39 Free Cash Flow to Firm -132.325 Million
Earnings Report2023-05-10
View SEC Filings from OCUL instead.

View recent insider trading info

Funds Holding OCUL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OCUL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-03-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-30:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Proposed Sales (Form 144)

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    44.6 Thousand total shares from 5 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WHITE CHRISTOPHER G CHIEF BUSINESS OFFICER

    • Officer
    94,766 2023-02-06 3

    MATTESSICH ANTONY C. PRESIDENT AND CEO

    • Officer
    • Director
    446,281 2023-02-06 2

    NOTMAN DONALD CHIEF FINANCIAL OFFICER

    • Officer
    139,387 2023-02-06 2

    OZDEN RABIA GURSES CHIEF MEDICAL OFFICER

    • Officer
    101,363 2023-02-06 4

    STRASSBURGER PHILIP C. GENERAL COUNSEL

    • Officer
    109,071 2023-02-06 2

    SUMMER ROAD LLC

    • 10% Owner
    6,122,089 2022-11-07 3

    HEIER JEFFREY S.

    • Director
    16,000 2022-10-17 3

    RAINES MERILEE

    • Director
    35,733 2022-06-16 1

    LINDSTROM RICHARD L MD

    • Director
    135,202 2022-06-16 2

    WARDEN CHARLES M

    • Director
    75,264 2022-06-16 1

    WILLIAMS LESLIE J.

    • Director
    40,233 2022-06-16 1

    HONG SEUNG SUH

    • Director
    35,733 2022-06-16 1

    GOLDSTEIN MICHAEL H. PRESIDENT, OPHTHALMOLOGY & CMO

    • Officer
    503,335 2022-02-03 0

    PEACOCK BRUCE

    • Director
    18,000 2021-06-18 0

    KITCHEN PATRICIA CHIEF OPERATING OFFICER

    • Officer
    0 2021-02-17 0

    OPALEYE MANAGEMENT INC.

    • PREVIOUSLY A 10% OWNER
    No longer subject to file 2020-04-03 0

    SAWHNEY AMARPREET CHAIRMAN OF THE BOARD

    • Officer
    • Director
    3,014,973 2019-06-06 0

    BOLLAG DANIEL M SR. VP REG. AFFAIRS & QUALITY

    • Officer
    0 2019-01-02 0

    HANLEY KEVIN F. SR. VP TECHNICAL OPERATIONS

    • Officer
    0 2019-01-02 0

    OSHEA WILLIAM J

    • Director
    0 2018-06-14 0

    CHADHA JASWINDER

    • Director
    0 2018-06-14 0

    GARVEY JAMES M

    • Director
    0 2017-06-01 0

    MIGAUSKY GEORGE V INTERIM CFO

    • Officer
    0 2017-04-06 0

    SMITH W BRADFORD CFO AND TREASURER

    • Officer
    0 2017-01-31 0

    FORTUNE JAMES CHIEF OPERATING OFFICER

    • Officer
    0 2017-01-31 0

    ANKERUD ERIC SEE REMARKS

    • Officer
    0 2017-01-31 0

    TALAMO JONATHAN H. CHIEF MEDICAL OFFICER

    • Officer
    0 2017-01-31 0

    HURLEY CHARLES ANDREW CHIEF COMMERCIAL OFFICER

    • Officer
    0 2017-01-31 0

    VERSANT VENTURE CAPITAL III, L.P.

    VERSANT SIDE FUND III, L.P.

    • 10% Owner
    No longer subject to file 2015-06-15 0

    SVLSF IV, LLC

    SV LIFE SCIENCES FUND IV (GP), L.P.

    SV LIFE SCIENCES FUND IV, L.P.

    SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.

    • 10% Owner
    No longer subject to file 2015-06-10 0

    POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

    POLARIS VENTURE PARTNERS V, L.P.

    POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

    POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

    POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

    • 10% Owner
    No longer subject to file 2015-02-02 0

    CHV II, L.P.

    ASCENSION HEALTH VENTURES II, LLC

    • 10% Owner
    4,046,430 2014-07-30 0

    CRANE ALAN L

    • Director
    0 2014-07-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MATTESSICH ANTONY C. - Director - Officer PRESIDENT AND CEO

    2023-02-08 19:29:42 -0500 2023-02-06 S 19,669 $4.24 d 446,281 direct yes -1.7766 46.9543 54.5685 5 -1.7766 2

    STRASSBURGER PHILIP C. - Officer GENERAL COUNSEL

    2023-02-08 19:31:48 -0500 2023-02-06 S 6,181 $4.24 d 109,071 direct yes -1.7766 46.9543 54.5685 5 -1.7766 2

    OZDEN RABIA GURSES - Officer CHIEF MEDICAL OFFICER

    2023-02-08 19:33:40 -0500 2023-02-06 S 6,416 $4.24 d 101,363 direct yes -1.7766 46.9543 54.5685 5 -1.7766 2

    NOTMAN DONALD - Officer CHIEF FINANCIAL OFFICER

    2023-02-08 19:32:37 -0500 2023-02-06 S 6,476 $4.24 d 139,387 direct yes -1.7766 46.9543 54.5685 5 -1.7766 2

    WHITE CHRISTOPHER G - Officer CHIEF BUSINESS OFFICER

    2023-02-08 19:38:30 -0500 2023-02-06 S 5,829 $4.24 d 94,766 direct yes -1.7766 46.9543 54.5685 5 -1.7766 2

    MATTESSICH ANTONY C. - Director - Officer PRESIDENT AND CEO

    2023-02-01 19:32:25 -0500 2023-01-30 A 176,300 a 465,950 direct 1.8868 -7.0755 16.9811 47.8774 12 -8.7264 7

    MATTESSICH ANTONY C. - Director - Officer PRESIDENT AND CEO

    2023-02-01 19:32:25 -0500 2023-01-30 A 536,900 a 536,900 direct

    NOTMAN DONALD - Officer CHIEF FINANCIAL OFFICER

    2023-02-01 19:33:27 -0500 2023-01-30 A 55,556 a 145,863 direct 1.8868 -7.0755 16.9811 47.8774 12 -8.7264 7

    NOTMAN DONALD - Officer CHIEF FINANCIAL OFFICER

    2023-02-01 19:33:27 -0500 2023-01-30 A 166,667 a 166,667 direct

    OZDEN RABIA GURSES - Officer CHIEF MEDICAL OFFICER

    2023-02-01 19:34:30 -0500 2023-01-30 A 50,000 a 50,000 direct

    OZDEN RABIA GURSES - Officer CHIEF MEDICAL OFFICER

    2023-02-01 19:34:30 -0500 2023-01-30 A 55,556 a 107,779 direct 1.8868 -7.0755 16.9811 47.8774 12 -8.7264 7

    OZDEN RABIA GURSES - Officer CHIEF MEDICAL OFFICER

    2023-02-01 19:34:30 -0500 2023-01-30 A 166,667 a 166,667 direct

    WHITE CHRISTOPHER G - Officer CHIEF BUSINESS OFFICER

    2023-02-01 19:36:49 -0500 2023-01-30 A 44,444 a 100,595 direct 1.8868 -7.0755 16.9811 47.8774 12 -8.7264 7

    WHITE CHRISTOPHER G - Officer CHIEF BUSINESS OFFICER

    2023-02-01 19:36:49 -0500 2023-01-30 A 133,333 a 133,333 direct

    STRASSBURGER PHILIP C. - Officer GENERAL COUNSEL

    2023-02-01 19:35:40 -0500 2023-01-30 A 55,556 a 115,252 direct 1.8868 -7.0755 16.9811 47.8774 12 -8.7264 7

    STRASSBURGER PHILIP C. - Officer GENERAL COUNSEL

    2023-02-01 19:35:40 -0500 2023-01-30 A 166,667 a 166,667 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 20:45:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 20:15:04 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 19:45:04 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 19:15:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 18:45:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 18:15:05 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 17:45:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 17:15:04 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 16:45:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 16:15:04 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 15:45:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 15:15:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 14:45:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 14:15:03 UTC 2.6487 1.9213 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 13:45:04 UTC 2.4407 2.1293 4000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 13:15:03 UTC 2.4407 2.1293 4100000
    OCULAR THERAPEUTIX INC OCUL 2023-03-22 12:45:03 UTC 2.4407 2.1293 4100000
    OCULAR THERAPEUTIX INC OCUL 2023-03-21 22:15:04 UTC 2.4407 2.1293 3000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-21 21:45:03 UTC 2.4407 2.1293 3000000
    OCULAR THERAPEUTIX INC OCUL 2023-03-21 21:15:03 UTC 2.4407 2.1293 3000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments